Tang H, Lu Y, Donahoo WT, Shao H, Shi L, Fonseca VA, et al
Eleven out of 15 studies reported changes in HbA1c, with the most significant reductions observed when compared to placebo
However, while data in mouse models are promising, there are currently no therapies currently in clinical trials focused on GPCR signaling to increase plasma GLP-1
But one study conducted in the United Kingdom in 2024 with 204 people with Alzheimers disease found that liraglutide helped to slow down cognitive decline by 18 percent over the course of a year compared with those taking a placebo (Manalac, Dec 2024)
'Gastric' hypoglycaemiaan important concept in diabetes management